IJSRP, Volume 3, Issue 2, February 2013 Edition [ISSN 2250-3153]
Dr. Balaji Chinnasami, Dr. V. Mangayarkarasi, Dr. A. Prema, Dr. Kanimozhi Sadasivam, Michael J Davis
Background: Conjugate typhoid vaccine can prevent increasing cases of typhoid in younger children. Commercially available conjugate vaccine has limited studies to support its use. Aims: To study the safety and immunogenicity of Vi conjugate typhoid vaccine (PedaTyphTM). Materials and Methods: Four hundred children with age <5 years were randomised to receive either one dose (Group A) or two doses (Group B) of vaccine. Adverse effects were monitored and paired blood samples were collected for immunogenicity. Due to inadequate funding analyses of group B could not be done. Results: Adverse events occurred in 17% and 21% of children after first and second doses respectively.